vopratelimab

Jounce’s latest setback dampens outlook for another cancer immunotherapy target
BioPharma Dive
Tue, 08/30/22 - 06:10 pm
Jounce Therapeutics
lung cancer
cancer immunotherapy
vopratelimab
Three Biotechs Shutter Clinical Programs After Futility Analysis or Failed Trials
BioSpace
Tue, 11/3/20 - 09:29 pm
Jounce Therapeutics
vopratelimab
Santhera
vamorolone
Puldysa
Aurinia Pharmaceuticals
FOS